ATN-103 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
46Malignant rheumatoid arthritis9

46. Malignant rheumatoid arthritis


Clinical trials : 4,325 Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-007185-33-NL
(EUCTR)
20/05/201028/09/2009A Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103Administered to Subjects With Active Rheumatoid Arthritis on a Background ofMethotrexateA Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103Administered to Subjects With Active Rheumatoid Arthritis on a Background ofMethotrexate Rheumatoid arthritis
MedDRA version: 12.0;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis
Product Name: ATN-103
Product Code: ATN-103
Wyeth Research Division of Wyeth Pharmaceuticals Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
240Phase 1/2Hungary;United Kingdom;Germany;Netherlands;Belgium
2EUCTR2009-015636-15-HU
(EUCTR)
25/03/201008/02/2010Rheumatoid arthritisAn Open-label Extension Study to Assess the Long-term Safety and Tolerability of ATN-103 in Subjects With Rheumatoid Arthritis Rheumatoid arthritis
MedDRA version: 13.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: ATN-103
Product Code: ATN-103
Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer CompanyNULLNot RecruitingFemale: yes
Male: yes
260Hungary;Russian Federation;Germany;Canada;Switzerland;Belgium;Japan;United States;South Africa
3EUCTR2008-007185-33-BE
(EUCTR)
01/02/201010/09/2009A Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103Administered to Subjects With Active Rheumatoid Arthritis on a Background ofMethotrexateA Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103Administered to Subjects With Active Rheumatoid Arthritis on a Background ofMethotrexate Rheumatoid arthritis
MedDRA version: 12.0;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis
Product Name: ATN-103
Product Code: ATN-103
Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer CompanyNULLNot RecruitingFemale: yes
Male: yes
240Phase 1/2Hungary;United Kingdom;Germany;Netherlands;Belgium
4NCT01063803
(ClinicalTrials.gov)
February 20102/2/2010Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid ArthritisAn Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid ArthritisRheumatoid ArthritisDrug: ATN-103AblynxNULLCompleted18 Years80 YearsBoth266Phase 2United States;Canada;Hungary;Japan;Russian Federation;Serbia;South Africa;Switzerland
5EUCTR2008-007185-33-DE
(EUCTR)
12/01/201002/09/2009A Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103Administered to Subjects With Active Rheumatoid Arthritis on a Background ofMethotrexateA Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103Administered to Subjects With Active Rheumatoid Arthritis on a Background ofMethotrexate Rheumatoid arthritis
MedDRA version: 12.0;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis
Product Name: ATN-103
Product Code: ATN-103
Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer CompanyNULLNot RecruitingFemale: yes
Male: yes
240Phase 1/2Hungary;United Kingdom;Germany;Netherlands;Belgium
6EUCTR2008-007185-33-GB
(EUCTR)
26/11/200928/07/2010A Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103Administered to Subjects With Active Rheumatoid Arthritis on a Background ofMethotrexateA Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103Administered to Subjects With Active Rheumatoid Arthritis on a Background ofMethotrexate Rheumatoid arthritis
MedDRA version: 12.0;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis
Product Name: ATN-103
Product Code: ATN-103
Wyeth Pharmaceuticals Inc., Acting through its division Wyeth Research, a Pfizer CompanyNULLNot RecruitingFemale: yes
Male: yes
240Phase 1/2Hungary;Germany;United Kingdom;Netherlands;Belgium
7NCT01007175
(ClinicalTrials.gov)
November 20092/11/2009Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid ArthritisA Randomized, Multicenter, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Clinical Efficacy Of ATN-103 Administered To Japanese Subjects With Active Rheumatoid Arthritis On A Background Of MethotrexateRheumatoid ArthritisBiological: ATN-103 10 mg q4wks;Biological: ATN-103 30 mg q4wks;Biological: ATN-103 80 mg q4wks;Biological: ATN-103 10 mg q8wks;Biological: ATN-103 80 mg q8wksAblynxNULLCompleted20 Years75 YearsBoth60Phase 1/Phase 2Japan
8EUCTR2008-007185-33-HU
(EUCTR)
16/10/200909/09/2009A Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103Administered to Subjects With Active Rheumatoid Arthritis on a Background ofMethotrexateA Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103Administered to Subjects With Active Rheumatoid Arthritis on a Background ofMethotrexate Rheumatoid arthritis
MedDRA version: 12.0;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis
Product Name: ATN-103
Product Code: ATN-103
Wyeth Research Division of Wyeth Pharmaceuticals Inc.NULLNot RecruitingFemale: yes
Male: yes
240Phase 1/2Hungary;United Kingdom;Germany;Netherlands;Belgium
9NCT00959036
(ClinicalTrials.gov)
September 200913/8/2009Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid ArthritisA Seamless, Phase 1/2, Multiple Ascending Dose, Proof Of Concept Study Of ATN-103 Administered To Subjects With Active Rheumatoid Arthritis On A Background Of MethotrexateActive Rheumatoid ArthritisDrug: ATN-103;Drug: Placebo;Drug: MethotrexateAblynxNULLCompleted18 Years80 YearsBoth252Phase 1/Phase 2United States;Belgium;Canada;Germany;Hungary;Russian Federation;Serbia;South Africa;Switzerland